New ALS drug put to the test in major trial
NCT ID NCT05740813
First seen Nov 16, 2025 · Last updated May 14, 2026 · Updated 20 times
Summary
This clinical trial tested an investigational drug called ABBV-CLS-7262 in 310 people with ALS, a progressive nerve disease. The goal was to see if the drug could slow disease progression and improve survival over 24 weeks. Researchers measured changes in physical function and breathing ability to evaluate safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Healey Center for ALS at Mass General
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.